Nocebo is the enemy, not placebo. A meta-analysis of reported side effects after placebo treatment in headaches

Cephalalgia

Volumn 31, Issue 5, 2011, Pages 550-561

  Mitsikostas, Dimos D ^a   Mantonakis, Leonidas I ^a   Chalarakis, Nikolaos G ^a  

^a ATHENS NAVAL HOSPITAL   (Greece)

Author keywords

cluster headache; Migraine; nocebo; placebo; tension type headache

Indexed keywords

ANTICONVULSIVE AGENT; BOTULINUM TOXIN A; CALCITONIN GENE RELATED PEPTIDE RECEPTOR ANTAGONIST; PLACEBO; TOPIRAMATE; TRIPTAN DERIVATIVE;

ADVERSE OUTCOME; AMNESIA; ANOREXIA; ARTICLE; CLINICAL PRACTICE; CLUSTER HEADACHE; HUMAN; META ANALYSIS; MIGRAINE; NOCEBO EFFECT; PLACEBO EFFECT; PRIMARY HEADACHE; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW; TENSION HEADACHE; TREATMENT DURATION; TREATMENT WITHDRAWAL;

HEADACHE; HUMANS; PATIENT DROPOUTS; PLACEBOS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 79953180062     PISSN: 03331024     EISSN: 14682982     Source Type: Journal    
DOI: 10.1177/0333102410391485     Document Type: Article

References (36)

1. Kennedy WP The nocebo reaction. Med World 1961 ; 95: 203-205.
2. Enck P., Benedetti F. and Schedlowski M. New insights into the placebo and nocebo responses. Neuron 2008 ; 59: 195-206. (Pubitemid 352033692)
3. Papadopoulos D. and Mitsikostas DD Nocebo effects in multiple sclerosis trials: a meta-analysis. Mult Scler 2010 ; 16: 816-828.
4. Colloca L., Sigaudo M. and Benedetti F. The role of learning in nocebo and placebo effects. Pain 2008 ; 136: 211-218.
5. Benedetti F., Amanzio M., Vighetti S. and Asteggiano G. The biochemical and neuroendocrine bases of the hyperalgesic nocebo effect. J Neurosci 2006 ; 26: 12014-12022. (Pubitemid 44772112)
6. Benedetti F., Pollo A., Lopiano L., Lanotte M., Vighetti S. and Rainero I. Conscious expectation and unconscious conditioning in analgesic, motor, and hormonal placebo/ nocebo responses. J Neurosci 2003 ; 23: 4315-4323. (Pubitemid 36958452)
7. Benedetti F., Amanzio M., Casadio C., Oliaro A. and Maggi G. Blockade of nocebo hyperalgesia by the cholecystokinin antagonist proglumide. Pain 1997 ; 71: 135-140. (Pubitemid 27232422)
8. Kong J., Gollub RL, Polich G., Kirsch I., Laviolette P., Vangel M., et al. A functional magnetic resonance imaging study on the neural mechanisms of hyperalgesic nocebo effect. J Neurosci 2008 ; 28: 13354-13362.
9. Scott DJ, Stohler CS, Egnatuk CM, Wang H., Koeppe RA and Zubieta JK Placebo and nocebo effects are defined by opposite opioid and dopaminergic responses. Arch Gen Psychiatry 2008 ; 65: 220-231. (Pubitemid 351214321)
10. Johansen O., Brox J. and Flaten MA Placebo and nocebo responses, cortisol, and circulating beta-endorphin. Psychosom Med 2003 ; 65: 786-790. (Pubitemid 37163384)
11. Evans WR Headaches and the nocebo effect. Headache 2003 ; 43: 1111-1115.
12. Lorenz J., Hauck M., Paur RC, Nakamura Y., Zimmermann R., Bromm B., et al. Cortical correlates of false expectations during pain intensity judgments-a possible manifestation of placebo/nocebo cognitions. Brain Behav Immun 2005 ; 19: 283-295. (Pubitemid 40797984)
13. Vase L., Robinson ME, Verne GN and Price DD The contributions of suggestion, desire, and expectation to placebo effects in irritable bowel syndrome patients. An empirical investigation. Pain 2003 ; 105: 17-25. (Pubitemid 37162469)
14. Barsky AJ, Saintfort R., Rogers MP and Borus JF Nonspecific medication side effects and the nocebo phenomenon. JAMA 2002 ; 287: 622-627. (Pubitemid 34252015)
15. Preston RA, Materson BJ, Reda DJ and Williams DW Placebo-associated blood pressure response and adverse effects in the treatment of hypertension: observations from a Department of Veterans Affairs Cooperative Study. Arch Intern Med 2000 ; 160: 1449-1454. (Pubitemid 30327447)
16. Reuter U., Sanchez del Rio M., Carpay JA, Boes CJ and Silberstein SD ; GSK Headache Masters Program. Placebo adverse events in headache trials: headache as an adverse event of placebo. Cephalalgia 2003 ; 23: 496-503. (Pubitemid 37114970)
17. Loder E., Goldstein R. and Biondi D. Placebo effects in oral triptan trials: the scientific and ethical rationale for continued use of placebo controls. Cephalalgia 2004 ; 25: 124-131. (Pubitemid 40193955)
18. Amanzion M., Corazzini LL, Vase L. and Benedetti F. A systematic review of adverse events in placebo groups of anti-migraine clinical trials. Pain 2009 ; 146: 261-269.
19. Moher D., Liberati A., Tetzlaff J. and Altman DG ; Prisma Grou p. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 2009 ; 151: 264-269.
20. Olivo SA, Macedo LG, Gadotti IC, Fuentes J., Stanton T. and Magee DJ Scales to assess the quality of randomized controlled trials: a systematic review. Phys Ther 2008 ; 88: 156-175. (Pubitemid 351210558)
21. Jadad AR, Moore RA, Carroll D., Jenkinson C., Reynolds DJ, Gavaghan DJ, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996 ; 17: 1-12. (Pubitemid 26120810)
22. DerSimonian R. and Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986 ; 7: 177-188. (Pubitemid 17189972)
23. Deeks JJ Systematic reviews of evaluations of diagnostic and screening tests. In: Egger M, Smith GD and Altman DG (eds) Systematic Reviews in Health Care: Meta-analysis in context. London: BMJ Books, 2001.
24. Harbord RM, Egger M. and Sterne JA A modified test for small-study effects in meta-analyses of controlled trials with binary endpoints. Stat Med 2006 ; 25: 3443-3457. (Pubitemid 44575162)
25. Egger M., Davey Smith G., Schneider M. and Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997 ; 315: 629-634. (Pubitemid 27387172)
26. Moerman DE Cultural variations in the placebo effect ulcers, anxiety and blood pressure. Med Anthropol Q 2000 ; 14: 51-72.
27. Uhlenhuth EH, Alexander PE, Dempsey GM, Jones W., Coleman BS and Swiontek AM Medication side effects in anxious patients: negative placebo responses. J Affect Dis 1998 ; 47: 183-190. (Pubitemid 28066774)
28. Benedetti F., Lanotte M., Lopiano L. and Colloca L. When words are painful: unraveling the mechanisms of the nocebo effect. Neuroscience 2007 ; 147: 260-271. (Pubitemid 46907442)
29. Connor KM, Shapiro RE, Diener HC, Lucas S., Kost J., Fan X., et al. Randomized, controlled trial of telcagepant for the acute treatment of migraine. Neurology 2009 ; 73: 970-977.
30. World Medical Association. World Medical Association Declaration of Helsinski: ethical principles for medical research involving human subjects. J Postgrad Med 2002 ; 48: 2006-2008.
31. Holroyd KA, Powers SW and Andrasik F. Methodological issues in clinical trials of drug and behavior therapies. Headache 2005 ; 45: 487-492. (Pubitemid 40847171)
32. Craig P., Dieppe P., Macintype S., Michie S., Nazzareth I. and Petticrew M. Developing and evaluating complex interventions: the new Medical Research Council guidance. BMJ 2008 ; 337: 979-983.
33. Colloca L. and Benedetti F. Nocebo hyperalgesia: how anxiety is turned into pain. Curr Opin Anaesthesiol 2007 ; 20: 435-439. (Pubitemid 47415134)
34. Stam AH, de Vries B., Janssens AC, Vanmolkot KR, Aulchenko YS and Henneman P. Shared genetic factors in migraine and depression. Evidence from a genetic isolate. Neurology 2010 ; 74: 288-294.
35. Mitsikostas DD and Thomas AM Comorbidity of headache and depressive disorders. Cephalalgia 1999 ; 19: 211-217. (Pubitemid 29268493)
36. Bigal ME and Lipton RB The epidemiology, burden, and comorbidities of migraine. Neurol Clin 2009 ; 27: 321-334.